Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlucoTrack ( (GCTK) ) has issued an announcement.
On June 25, 2025, Glucotrack, Inc. announced positive final results from its first-in-human clinical study of its Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association’s 85th Scientific Sessions. The study, conducted between December 2024 and January 2025, demonstrated the device’s excellent accuracy and safety, with a Mean Absolute Relative Difference (MARD) of 7.7% and no serious adverse events. The CBGM, which measures glucose directly from the blood, eliminates the lag time associated with traditional systems and offers a long-term, less intrusive solution for diabetes management. These results validate the device’s potential and position Glucotrack to advance into further clinical trials, potentially impacting diabetes care by providing a more reliable monitoring option.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.
GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.
To see Spark’s full report on GCTK stock, click here.
More about GlucoTrack
Glucotrack, Inc. is a medical device company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system that measures glucose levels directly from the blood, offering a more convenient and less intrusive solution for diabetes management.
Average Trading Volume: 81,680
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.54M
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.